{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:18:56Z","timestamp":1786979936830,"version":"build-2736575974"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,3,23]],"date-time":"2017-03-23T00:00:00Z","timestamp":1490227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,3,23]],"date-time":"2017-03-23T00:00:00Z","timestamp":1490227200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Cancer Institute (NCI) to MD Anderson Cancer Center in the form of the SPORE in Multiple Myeloma","award":["P50 CA142509"],"award-info":[{"award-number":["P50 CA142509"]}]},{"name":"Cancer Center Support Grant","award":["P30 CA16672"],"award-info":[{"award-number":["P30 CA16672"]}]},{"name":"Cancer Therapy Evaluation Program (CTEP) grant","award":["N01 CM-2011-0039"],"award-info":[{"award-number":["N01 CM-2011-0039"]}]},{"name":"Leukemia and Leukemia Society Translational Research Program Award"},{"name":"Multiple Myeloma SPORE"},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U10 CA032102, R01 CA184464, CA194264"],"award-info":[{"award-number":["U10 CA032102, R01 CA184464, CA194264"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"MD Anderson Cancer Center High-Risk Multiple Myeloma Moon Shot"},{"name":"Brock Family Myeloma Research Fund"},{"name":"Yates Ortiz Myeloma Fund"},{"name":"Diane and John Grace Family Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s00277-017-2980-3","type":"journal-article","created":{"date-parts":[[2017,3,23]],"date-time":"2017-03-23T19:35:15Z","timestamp":1490297715000},"page":"977-985","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed\/refractory multiple myeloma"],"prefix":"10.1007","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0630-8458","authenticated-orcid":false,"given":"Muhamed","family":"Baljevic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shadia","family":"Zaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veerabhadran","family":"Baladandayuthapani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan Heather","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia Morales","family":"de Partovi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzana","family":"Berkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behrang","family":"Amini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheeba K.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jatin J.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna M.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles S.","family":"Cleeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin Shelley","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M.","family":"Stellrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varsha","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Z.","family":"Orlowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,23]]},"reference":[{"key":"2980_CR1","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.1200\/JCO.2008.20.8983","volume":"27","author":"BD Smith","year":"2009","unstructured":"Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA (2009) Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol Off J Am Soc Clin Oncol 27:2758\u20132765","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2980_CR2","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/leu.2011.196","volume":"26","author":"SK Kumar","year":"2012","unstructured":"Kumar SK, Lee JH, Lahuerta JJ et al (2012) Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 26:149\u2013157","journal-title":"Leukemia"},{"key":"2980_CR3","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1182\/blood-2003-12-4386","volume":"104","author":"EPM Tjin","year":"2004","unstructured":"Tjin EPM, Derksen PWB, Kataoka H, Spaargaren M, Pals ST (2004) Multiple myeloma cells catalyze hepatocyte growth factor (HGF) activation by secreting the serine protease HGF-activator. Blood 104:2172\u20132175","journal-title":"Blood"},{"key":"2980_CR4","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/j.1600-0609.2008.01130.x","volume":"81","author":"KF Wader","year":"2008","unstructured":"Wader KF, Fagerli UM, Holt RU et al (2008) Elevated serum concentrations of activated hepatocyte growth factor activator in patients with multiple myeloma. Eur J Haematol 81:380\u2013383","journal-title":"Eur J Haematol"},{"key":"2980_CR5","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1182\/blood.V99.4.1405","volume":"99","author":"PWB Derksen","year":"2002","unstructured":"Derksen PWB, Keehnen RMJ, Evers LM, van Oers MHJ, Spaargaren M, Pals ST (2002) Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes met signaling in multiple myeloma. Blood 99:1405\u20131410","journal-title":"Blood"},{"key":"2980_CR6","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2141.2004.05299.x","volume":"128","author":"NF Andersen","year":"2005","unstructured":"Andersen NF, Standal T, Nielsen JL et al (2005) Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival. Br J Haematol 128:210\u2013217","journal-title":"Br J Haematol"},{"key":"2980_CR7","doi-asserted-by":"publisher","first-page":"6686","DOI":"10.1158\/1078-0432.CCR-04-0874","volume":"10","author":"H Hov","year":"2004","unstructured":"Hov H, Holt RU, R\u00f8 TB et al (2004) A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells. Clinical cancer research : an official journal of the American Association for Cancer Research 10:6686\u20136694","journal-title":"Clinical cancer research : an official journal of the American Association for Cancer Research"},{"key":"2980_CR8","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/1756-8722-6-92","volume":"6","author":"CJ Phillip","year":"2013","unstructured":"Phillip CJ, Zaman S, Shentu S et al (2013) Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines. J Hematol Oncol 6:92","journal-title":"J Hematol Oncol"},{"key":"2980_CR9","doi-asserted-by":"publisher","first-page":"5796","DOI":"10.1158\/1078-0432.CCR-14-0847","volume":"20","author":"A Ferrucci","year":"2014","unstructured":"Ferrucci A, Moschetta M, Frassanito MA et al (2014) A HGF\/cMET autocrine loop is operative in multiple myeloma bone marrow endothelial cells and may represent a novel therapeutic target. Clinical cancer research: an official journal of the American Association for Cancer Research. 20:5796\u20135807","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research."},{"key":"2980_CR10","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.neo.2015.01.006","volume":"17","author":"S Zaman","year":"2015","unstructured":"Zaman S, Shentu S, Yang J et al (2015) Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells. Neoplasia 17:289\u2013300","journal-title":"Neoplasia"},{"key":"2980_CR11","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1200\/JCO.2010.31.0367","volume":"29","author":"TA Yap","year":"2011","unstructured":"Yap TA, Olmos D, Brunetto AT et al (2011) Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J Clin Oncol Off J Am Soc Clin Oncol 29:1271\u20131279","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2980_CR12","doi-asserted-by":"publisher","first-page":"5894","DOI":"10.1002\/cncr.27582","volume":"118","author":"AJ Wagner","year":"2012","unstructured":"Wagner AJ, Goldberg JM, Dubois SG et al (2012) Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial. Cancer 118:5894\u20135902","journal-title":"Cancer"},{"key":"2980_CR13","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1200\/JCO.2014.60.7317","volume":"33","author":"G Scagliotti","year":"2015","unstructured":"Scagliotti G, von Pawel J, Novello S et al (2015) Phase III multinational, randomized, double-blind, placebo-controlled study of Tivantinib (ARQ 197) plus Erlotinib versus Erlotinib alone in previously treated patients with locally advanced or metastatic Nonsquamous non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol 33:2667\u20132674","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2980_CR14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1756-8722-6-13","volume":"6","author":"D Jones","year":"2013","unstructured":"Jones D, Vichaya EG, Wang XS et al (2013) Validation of the M. D. Anderson symptom Inventory multiple myeloma module. J Hematol Oncol 6:13","journal-title":"J Hematol Oncol"},{"key":"2980_CR15","doi-asserted-by":"publisher","first-page":"11009","DOI":"10.1074\/jbc.M110.180208","volume":"286","author":"CC Bjorklund","year":"2011","unstructured":"Bjorklund CC, Ma W, Wang Z-Q et al (2011) Evidence of a role for activation of Wnt\/beta-catenin signaling in the resistance of plasma cells to lenalidomide. J Biol Chem 286:11009\u201311020","journal-title":"J Biol Chem"},{"key":"2980_CR16","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1158\/1055-9965.EPI-10-0565","volume":"19","author":"W Ma","year":"2010","unstructured":"Ma W, Wang M, Wang ZQ et al (2010) Effect of long-term storage in TRIzol on microarray-based gene expression profiling. Cancer Epidemiol Biomark Prev 19:2445\u20132452","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"2980_CR17","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nature07064","volume":"454","author":"AL Shaffer","year":"2008","unstructured":"Shaffer AL, Emre NC, Lamy L et al (2008) IRF4 addiction in multiple myeloma. Nature 454:226\u2013231","journal-title":"Nature"},{"key":"2980_CR18","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1182\/blood.V88.10.3998.bloodjournal88103998","volume":"88","author":"M B\u00f6rset","year":"1996","unstructured":"B\u00f6rset M, Hjorth-Hansen H, Seidel C, Sundan A, Waage A (1996) Hepatocyte growth factor and its receptor c-met in multiple myeloma. Blood 88:3998\u20134004","journal-title":"Blood"},{"key":"2980_CR19","doi-asserted-by":"publisher","first-page":"24655","DOI":"10.1074\/jbc.271.40.24655","volume":"271","author":"M Borset","year":"1996","unstructured":"Borset M, Lien E, Espevik T, Helseth E, Waage A, Sundan A (1996) Concomitant expression of hepatocyte growth factor\/scatter factor and the receptor c-MET in human myeloma cell lines. J Biol Chem 271:24655\u201324661","journal-title":"J Biol Chem"},{"key":"2980_CR20","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1182\/blood.V91.3.806","volume":"91","author":"C Seidel","year":"1998","unstructured":"Seidel C, B\u00f8rset M, Turesson I, Abildgaard N, Sundan A, Waage A (1998) Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic myeloma study group. Blood 91:806\u2013812","journal-title":"Blood"},{"key":"2980_CR21","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1046\/j.0007-1048.2002.03364.x","volume":"116","author":"T Iwasaki","year":"2002","unstructured":"Iwasaki T, Hamano T, Ogata A, Hashimoto N, Kitano M, Kakishita E (2002) Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma. Br J Haematol 116:796\u2013802","journal-title":"Br J Haematol"},{"key":"2980_CR22","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1046\/j.1365-2141.2002.03898.x","volume":"119","author":"C Seidel","year":"2002","unstructured":"Seidel C, Lenhoff S, Brabrand S et al (2002) Hepatocyte growth factor in myeloma patients treated with high-dose chemotherapy. Br J Haematol 119:672\u2013676","journal-title":"Br J Haematol"},{"key":"2980_CR23","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/ajh.10304","volume":"72","author":"MG Alexandrakis","year":"2003","unstructured":"Alexandrakis MG, Passam FH, Sfiridaki A, Kandidaki E, Roussou P, Kyriakou DS (2003) Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity. Am J Hematol 72:229\u2013233","journal-title":"Am J Hematol"},{"key":"2980_CR24","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/BF02850052","volume":"23","author":"IO Kara","year":"2006","unstructured":"Kara IO, Sahin B, Gunesacar R, Unsal C (2006) Clinical significance of hepatocyte growth factor, platelet-derived growth factor-AB, and transforming growth factor-alpha in bone marrow and peripheral blood of patients with multiple myeloma. Adv Ther 23:635\u2013645","journal-title":"Adv Ther"},{"key":"2980_CR25","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1046\/j.1365-2141.1999.01651.x","volume":"106","author":"I Turesson","year":"1999","unstructured":"Turesson I, Abildgaard N, Ahlgren T et al (1999) Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factors. Br J Haematol 106:1005\u20131012","journal-title":"Br J Haematol"},{"key":"2980_CR26","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/j.1600-0609.2009.01396.x","volume":"84","author":"P Ludek","year":"2010","unstructured":"Ludek P, Hana S, Zdenek A et al (2010) Treatment response to bortezomib in multiple myeloma correlates with plasma hepatocyte growth factor concentration and bone marrow thrombospondin concentration. Eur J Haematol 84:332\u2013336","journal-title":"Eur J Haematol"},{"key":"2980_CR27","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1034\/j.1600-0609.2001.00348.x","volume":"66","author":"O Sezer","year":"2001","unstructured":"Sezer O, Jakob C, Eucker J et al (2001) Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma. Eur J Haematol 66:83\u201388","journal-title":"Eur J Haematol"},{"key":"2980_CR28","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s00277-009-0834-3","volume":"89","author":"L Pour","year":"2010","unstructured":"Pour L, Svachova H, Adam Z et al (2010a) Levels of angiogenic factors in patients with multiple myeloma correlate with treatment response. Ann Hematol 89:385\u2013389","journal-title":"Ann Hematol"},{"key":"2980_CR29","doi-asserted-by":"publisher","first-page":"29","DOI":"10.4149\/neo_2010_01_029","volume":"57","author":"L Pour","year":"2010","unstructured":"Pour L, Svachova H, Adam Z et al (2010b) Pretreatment hepatocyte growth factor and thrombospondin-1 levels predict response to high-dose chemotherapy for multiple myeloma. Neoplasma 57:29\u201334","journal-title":"Neoplasma"},{"key":"2980_CR30","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s00280-008-0770-2","volume":"63","author":"CJ Phillip","year":"2009","unstructured":"Phillip CJ, Stellrecht CM, Nimmanapalli R, Gandhi V (2009) Targeting MET transcription as a therapeutic strategy in multiple myeloma. Cancer Chemother Pharmacol 63:587\u2013597","journal-title":"Cancer Chemother Pharmacol"},{"key":"2980_CR31","doi-asserted-by":"publisher","first-page":"9913","DOI":"10.1158\/0008-5472.CAN-07-0770","volume":"67","author":"CM Stellrecht","year":"2007","unstructured":"Stellrecht CM, Phillip CJ, Cervantes-Gomez F, Gandhi V (2007) Multiple myeloma cell killing by depletion of the MET receptor tyrosine kinase. Cancer Res 67:9913\u20139920","journal-title":"Cancer Res"},{"key":"2980_CR32","doi-asserted-by":"publisher","first-page":"20666","DOI":"10.1074\/jbc.M110.213801","volume":"286","author":"S Eathiraj","year":"2011","unstructured":"Eathiraj S, Palma R, Volckova E et al (2011) Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-met) protein autophosphorylation by ARQ 197. J Biol Chem 286:20666\u201320676","journal-title":"J Biol Chem"},{"issue":"19","key":"2980_CR33","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1182\/blood-2016-01-694786","volume":"127","author":"N Lendvai","year":"2016","unstructured":"Lendvai N, Yee AJ, Tsakos I et al (2016) Phase IB study of cabozantinib in patients with relapsed and\/or refractory multiple myeloma. Blood 127(19):2355\u20132356","journal-title":"Blood"},{"key":"2980_CR34","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1038\/sj.leu.2402182","volume":"15","author":"S Verstovsek","year":"2001","unstructured":"Verstovsek S, Kantarjian H, Estey E et al (2001) Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndrome. Leukemia 15:1165\u20131170","journal-title":"Leukemia"},{"key":"2980_CR35","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s005990050073","volume":"29","author":"M Sakon","year":"1999","unstructured":"Sakon M, Kita Y, Takeda Y et al (1999) Measurement of hepatocyte growth factor in serum and plasma. Int J Clin Lab Res 29:110\u2013113","journal-title":"Int J Clin Lab Res"},{"key":"2980_CR36","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1158\/1078-0432.CCR-12-3459","volume":"19","author":"C Basilico","year":"2013","unstructured":"Basilico C, Pennacchietti S, Vigna E et al (2013) Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET. Clinical cancer research: an official journal of the American Association for Cancer Research. 19:2381\u20132392","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research."},{"key":"2980_CR37","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.1158\/0008-5472.CAN-12-3256","volume":"73","author":"R Katayama","year":"2013","unstructured":"Katayama R, Aoyama A, Yamori T et al (2013) Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition. Cancer Res 73:3087\u20133096","journal-title":"Cancer Res"},{"key":"2980_CR38","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.1158\/1078-0432.CCR-13-0039","volume":"19","author":"M Moschetta","year":"2013","unstructured":"Moschetta M, Basile A, Ferrucci A et al (2013) Novel targeting of phospho-cMET overcomes drug resistance and induces antitumor activity in multiple myeloma. Clinical cancer research: an official journal of the American Association for Cancer Research 19:4371\u20134382","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-017-2980-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-017-2980-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-017-2980-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T02:02:31Z","timestamp":1719108151000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-017-2980-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,23]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["2980"],"URL":"https:\/\/doi.org\/10.1007\/s00277-017-2980-3","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,23]]},"assertion":[{"value":"27 July 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflicts of interest relevant to this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}